The problem of viral resistance in chronic hepatitis B therapy
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2009, Vol 26, Issue 3
Abstract
Available agents for the treatment of chronic HBV infection include interferon-alpha, the nucleoside analogues lamivudine, telbivudine, entecavir and the noucleotide analogue adefovir and tenofovir. When nucleoside-nucleotide analogues are used, patients require a long duration of treatment, especially in HBeAg negative disease, with the potential for developing antiviral resistance, which limits their long-term effectiveness. Interferon-alpha lacks viral resistance selection. Resistance rates vary by compound. Lamivudine is associated with the development of viral resistance in up to 70% within 5 years, adefovir dipivoxil in 29% after 5 years, entecavir in <1% in naive patients for up to 4 years (39% in 4 years in lamivudine-resistant patients) and telbivudine in 22% after 2 years of therapy. Clinical consequences of nucleoside-noucleotide resistance include loss of viral response (i.e., a rise in serum HBV DNA), biochemical dysfunction with an increase in aminotransferases, and overt hepatic failure (in patients with more advanced underlying liver disease). The initial choice of antiviral agent should take into consideration both the potency and the incidence of resistance, with serial HBV DNA determination to confirm adequate viral suppression. A suboptimal response to therapy with continued high-level replication identifies a patient at high risk for viral resistance, and is an indication for a change in antiviral strategy. Routine on-treatment monitoring of HBV DNA levels is imperative for detecting virologic breakthrough as early as possible, and for transitioning patients to rescue therapy before biochemical failure and loss of response occurs. For lamivudine resistant HBV infection, adefovir or tenofovir, and for adefovir resistance lamivudine should be added. In conclusion, monitoring for drug resistance during therapy and its prompt management are crucial in managing the antiviral treatment of HBV patients.
Authors and Affiliations
S. DOURAKIS
Keywords
Related Articles
- EP ID EP160128
- DOI -
- Views 64
- Downloads 0
Prevention of thromboembolic events in atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia of clinical importance, and is associated with increased risk of cardiovascular morbidity and mortality. The prevalence in the general population is 1% and increases...
Metabolic acidosis in rhabdomyolysis: Pathophysiological mechanisms
Rhabdomyolysis is defined as a syndrome which occurs after damage/breakdown (lysis) of skeletal muscle cells. The causes of rhabdomyolysis can be divided into natural and unnatural. Large quantities of breakdown products...
Lymphedema after maxillary surgery: Factors affecting its development
OBJECTIVE Lymphedema is the most important complication of axillary lymph node dissection (ALND), which is an important component of the surgical treatment of breast cancer. In this retrospective study, the relevant data...
Intestinal malrotation complicated by midgut volvulus in a male adult
No abstract available
Cost- and time-effectiveness of application of MALDI-TOF mass spectrometry methodology in a food and water microbiology laboratory
No abstract available